ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO745

Outcomes of Foam Sclerotherapy for Large Kidney/Liver Cysts using Multi-Stage (Same/Next Day) and Multiple Sequential Procedures

Session Information

Category: Genetic Diseases of the Kidneys

  • 1201 Genetic Diseases of the Kidneys: Cystic

Authors

  • Howe, Cassie, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Helland, Ryan, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Gregory, Adriana, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Kline, Timothy L., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Vaughan, Lisa E., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Torres, Vicente E., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Hogan, Marie C., Mayo Clinic Minnesota, Rochester, Minnesota, United States
Background

We have been performing sotradecol foam sclerotherapy (SFS) outpatient procedures to ablate liver/kidney cysts. SFS has led to substantial reductions in Targeted Kidney & Liver Cyst (TKCV/TLCVs), total kidney/liver volumes (TKV/TLV), improved QOL, & augments cyst volume reduction in addition to tolvaptan (kidney cysts) & octreotide (liver cysts). We examined efficacy in individuals with multiple large cysts who opt to undergo multiple or multi-stage SFS (same day or 2 consecutive days).

Methods

Kidneys & liver were segmented using a deep-learning algorithm & cysts segmented using semi-automated segmentation software, pre & 4+ mo post SFS. Wilcoxon tests assessed %△ pre/post SFS. Median % △ TKCV/TLCVs were calculated (per-patient) by taking median %△ of targeted cysts within patient & compared to outcomes from single stage cyst procedures.

Results

For multiple liver procedures,(n=15) median △% TKCV/TLCVs was -76.5% [IQR, -90.3%, -42.8%, P<0.001] & △TLV % -1.9% [IQR, -7.4%, 0.42%, P=0.11] (Fig 1). For patients undergoing multiple kidney procedures (n=16), median % △TKCV was -88.8% [IQR, -95.1%, -82.0%, P<0.001] & △% TKV -13% [IQR, -23.8%, -4.9%, P<0.001]. Only 5 had multi-stage liver procedures; median △% TLCV post SFS -73% [IQR, -93%, -71%, P=0.06], & only 2 underwent multi-stage kidney procedures; median △% TKCV -52%[IQR, -73.5%, -31%, P=0.5].

Conclusion

Multiple SFS procedures led to substantial reductions in TKCV/TLCV/TKV/TLV; data on patients who underwent multi-stage procedures were sparse, but still demonstrated positive results. SFS is feasible & convenient for patients seeking ablation of multiple cysts in a single 1 or 2 day session. Multiple & multi-stage SFS appear to be effective for patients with high cyst burden mainly due to a limited number of large cysts, with good patient satisfaction.

Percent Change in Targeted Cyst Volumes, Liver & Kidney Volumes. Black bars: % △ of each cyst. Black dots: median % △within each participant. Dashed line: 0% change.

Funding

  • NIDDK Support